Cefodizime is a third-generation cephalosporin antibiotic with a broad spectrum of antibacterial activity. Cefodizime has no renal toxic effect, good tolerance, and immune regulation activity.

Cefodizime is a bactericidal antibiotic having a high affinity for penicillin-binding proteins lA/B, 2, and 3 of E. coli. Cefodizime inhibits other Gram-negative bacteria including Haemophilus irifluenzae, Neisseria gonorrhoeae, Moraxella catarrhalis, and Neisseria meningitidis. Cefodizime has marginal but variable inhibitory activity against Citrobacter species including Serratia marcescens and Citrobacter freundii. The in vitro concentrations of Cefodizime resulting in bactericidal activity against susceptible strains of Gram-positive and Gram-negative bacteria are generally similar to the minimum inhibitory concentrations [1].

Cefodizime has activity comparable to Cefotaxime and Ceftazidime, and greater than that of Cefoperazone, Latamoxef, Cefuroxime, or cefazolin for 8 hours after a single subcutaneous dose of 50 mg/kg, in experimentally-induced K. pneumoniae respiratory tract infections in mice. However, unlike these cephalosporins, Cefodizime continues to demonstrate pronounced bactericidal activity for at least 48 hours after a single injection. Complete bacterial clearance from the lung is achieved within 48 hours in 50% of the mice although Cefodizime is no longer detectable in the serum [1].

69739-16-8

C20H20N6O7S4

584.67

Cefodizime

DMSO:20.83 mg/mL (35.63 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years